U.S. Patent Office Grants Human BioSystems Its Third Patent: U.S. Patent #7/029,839, 'Methods & Solutions for Storing Donor Organs'
Wednesday May 10, 10:30 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 10, 2006 -- Human BioSystems (OTC BB:HBSC.OB - News), developer of preservation platforms for organs and other biomaterials, announced today that the U.S. Patent Office approved its patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. patent number 7/029,839. The current shelf-life of human donor organs is very short -- depending upon the organ, they must be transplanted within 3 to 36 hours. While maintaining viability, quality and safety, the Human BioSystems technology is designed to extend the shelf life of these organs longer than is now possible.
"We believe that Human BioSystems is the first to fill a current need of the medical community by providing a method of organ preservation that is estimated to save millions of dollars each year in anti-rejection drugs alone as a result having more time to have a better donor/recipient match. With more than 173,000 patients on transplant waiting lists, this new organ preservation technology can save untold lives. Longer shelf life of organs should benefit patients, surgeons, hospitals and insurance companies," explained Luis Toledo, MD, Chief Medical Officer of Human BioSystems.
Human BioSystems has two earlier approved patents: "Method & Apparatus for Preserving Biological Materials," US patent no. 6,413,713, and "Methods and Apparatuses for Preserving Platelets," U.S. Patent No. 6,828,090.
"With the granting of this third patent, we are confident that we will have more possibilities to continue to secure strategic alliances of partners as we progress through our testing phases," stated David Winter, MD, President of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Yes International
Rich Kaiser
Investor Relations
(800) 631-8127
rich@yesinternational.com
Source: Human BioSystems
My posts are not buy or sell recommendations. I may buy, sell,own, go long and short on stocks I post about.
DO YOUR DD!
